Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Di | H.C. Wainwright Affirms Buy Rating on Alto Neuroscience (ANRO), Sets $10 PT | 1 | Insider Monkey | ||
ALTO NEUROSCIENCE Aktie jetzt für 0€ handeln | |||||
Di | Alto Neuroscience Adds 'Intriguing' Depression Asset Via Over $100 Million Deal | 2 | Benzinga.com | ||
Di | Alto Neuroscience, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
Di | Alto Neuroscience acquires novel TRD treatment candidate | 1 | Investing.com | ||
29.05. | Alto Neuroscience reports progress in depression drug trials | 2 | Investing.com | ||
14.05. | Alto Neuroscience, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
20.03. | Alto Neuroscience, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 3 | SEC Filings | ||
20.03. | Alto Neuroscience GAAP EPS of -$2.50 | 2 | Seeking Alpha | ||
20.03. | Alto Neuroscience, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
20.03. | Alto Neuroscience, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
12.02. | Stifel maintains Buy on Alto Neuroscience stock, $10 target | 2 | Investing.com | ||
12.02. | Alto Neuroscience macht Fortschritte bei Studie zur Behandlung von Depressionen | 2 | Investing.com Deutsch | ||
12.02. | Alto Neuroscience, Inc. - 8-K, Current Report | - | SEC Filings | ||
03.02. | Alto Neuroscience, Inc. - 8-K, Current Report | - | SEC Filings | ||
16.01. | Alto Neuroscience, Inc. - 8-K, Current Report | - | SEC Filings | ||
12.11.24 | Alto Neuroscience Reports Third Quarter 2024 Financial Results and Recent Business Highlights | 148 | Business Wire | MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Alto Neuroscience, Inc. ("Alto") (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric... ► Artikel lesen | |
13.08.24 | Alto Neuroscience Reports Second Quarter 2024 Financial Results and Recent Business Highlights | 351 | Business Wire | MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Alto Neuroscience, Inc. ("Alto") (NYSE: ANRO) today reported financial results for the second quarter ended June 30, 2024, and highlighted recent corporate... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
BIONTECH | 95,35 | +0,05 % | Summit Therapeutics crasht - BioNTech in Sippenhaft | Wie gewonnen, so zerronnen: Die Aktie von Summit Therapeutics brach am vergangenen Freitag an der Nasdaq um rund 30 Prozent ein. Weitere Studiendaten zum großen Hoffnungsträger Ivonescimab, den die... ► Artikel lesen | |
CUREVAC | 3,830 | -0,83 % | Kauf-Alarm bei CureVac: Insider decken sich massenhaft mit Aktien ein - Das müssen Sie jetzt beachten! | ||
AMGEN | 254,90 | +0,08 % | Amgen Says Imdelltra Cut Risk Of Death By 40% In Small Cell Lung Cancer Patients | THOUSAND OAKS (dpa-AFX) - Amgen Inc. (AMGN) Monday announced positive interim results from the Phase 3 DeLLphi-304 study showing Imdelltra reduced the risk of death by 40% and significantly... ► Artikel lesen | |
NOVAVAX | 6,520 | -0,20 % | Aktien New York: Rücksetzer nach US-Bonitätsabstufung verpufft | NEW YORK (dpa-AFX) - Die Abstufung der US-Kreditwürdigkeit durch Moody?s hat die Anleger in New York am Montag nicht lange beeindruckt. Benoit Anne, Anleiheexperte bei MFS Investment Management, verwies... ► Artikel lesen | |
BIOGEN | 116,70 | -0,09 % | DAX tritt auf der Stelle - Nvidia & Biogen mit Überraschung! Gold, EUR & Aktien im Chartcheck | ||
MAINZ BIOMED | 2,775 | -100,00 % | MAINZ BIOMED N.V. - 6-K, Report of foreign issuer | ||
VIKING THERAPEUTICS | 24,220 | -0,78 % | Viking Therapeutics auf Jefferies-Konferenz: Vielversprechendes Abnehm-Medikament | ||
INTELLIA THERAPEUTICS | 7,146 | +0,37 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | CAMBRIDGE, Mass., June 05, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies... ► Artikel lesen | |
BIOCRYST PHARMACEUTICALS | 9,668 | -0,17 % | BioCryst Pharmaceuticals, Inc.: BioCryst Achieves Reimbursement for ORLADEYO Across all Major European Countries | RESEARCH TRIANGLE PARK, N.C., June 06, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that, following a positive recommendation from the Zorginstituut Nederland... ► Artikel lesen | |
TEMPUS AI | 54,74 | +0,51 % | Opening Bell: Constellation Energy, Vistra, Netflix, Applied Digital, Steel Dyn., Pony.ai, Tempus AI | Zum Wochenauftakt schwankten die US-Börsen zwischen neuen Zolldrohungen und der Hoffnung auf sinkende Zinsen. Zwar sorgte US-Präsident Trumps verschärfte Rhetorik im Handelsstreit mit China zunächst... ► Artikel lesen | |
SAREPTA THERAPEUTICS | 38,180 | +1,17 % | FDA Grants Platform Technology Status To Sarepta's RAAVrh74 Vector | WASHINGTON (dpa-AFX) - Sarepta Therapeutics (SRPT), Wednesday announced that the FDA has designated its rAAVrh74 viral vector used in the investigational gene therapy SRP-9003 for limb-girdle... ► Artikel lesen | |
CARDIOL THERAPEUTICS | 1,218 | -1,30 % | H.C. Wainwright initiates Cardiol Therapeutics stock with buy rating | ||
PACIFIC BIOSCIENCES OF CALIFORNIA | 1,000 | +1,26 % | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. - 8-K, Current Report | ||
EXELIXIS | 37,400 | -0,93 % | BofA Hikes Exelixis, Inc. (EXEL) Target Amid CRC Caution | ||
VAXART | 0,364 | +2,42 % | Vaxart, Inc.: Vaxart Announces Adjournment of Annual Meeting of Stockholders |